Gene Expression and Diagnosis of Diabetes

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R42DK065388-02
Agency Tracking Number: DK065388
Amount: $917,003.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2005
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Arthrochip, Llc, 117 Bromley Park Ln, Franklin, TN, 37069
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 THOMAS AUNE
 (615) 343-7485
 thomas.aune@vanderbilt.edu
Business Contact
Phone: (615) 343-4208
Research Institution
 UNIVERSITY OF TEXAS SOUTHWESTEN MEDICAL SCHOOL
 5323 HARRY HINES BLVD.
DALLAS, TX, 75390
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The subsets of DM differ in pathogenesis, treatment and prognosis. Using microarray technology, we have compared differences in gene expression in peripheral blood mononuclear cells among patients with autoimmunity, including type I DM, and patients with non-autoimmune Type II DM. In Phase I, we investigated differences in gene expression between the DM types in adults and children. The findings from these studies suggest that we can readily identify subgroups of patients based on the gene expression patterns. The goal of our phase II application is to take these diagnostic tests closer to the marketplace. We have the following four specific aims: I. We will expand our microarray analysis using a larger cohort of individuals with diabetes from different racial backgrounds (Caucasian, African-American, and Hispanic) and different geographical locations to validate our results and to further test the notion that two classes of type I diabetes exist in the human population. II. We propose to validate identity of clones that exhibit extremes in hybridization among the control and different disease groups and develop "mini-microarray" and quantitative PCR tests that distinguish among the different disease groups. III. We will test these platforms by analyzing blood samples from a large cohort of control and diabetic individuals. IV. We will validate the diagnostic test in a cohort of individuals with an initial diagnosis of hyperglycemia. Long-term goals are to use results from microarray experiments to develop tests that have predictive value for the therapeutic management of individuals with autoimmune and non-autoimmune diseases. These include tests that classify diseases, predict severity, and predict optimal therapeutic options.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government